Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions showcase a strong interest and deep engagement with the research, as evidenced by phrases like 'ketamine wins big' and references to specific trial results such as remission rates, indicating enthusiasm for the potential of ketamine as an effective treatment. The tone and context reflect a recognition of the study's importance, with many emphasizing its promising results and possible influence on future depression therapies.
Most discussions support the findings of the study, emphasizing its positive results and potential clinical implications, evidenced by comments like 'Ketamine Wins Big' and mentions of promising trial outcomes.
There is a high level of curiosity, as participants refer to multiple studies, dosing details, and comparisons to existing treatments, indicating they find the research relevant and worth exploring.
Many discussions delve into details about the methodology and implications, with references to specific trial results and citations, showing deep involvement in understanding the topic.
Several posts highlight the trial’s significance, considering it a potential breakthrough in treating resistant depression and calling it a 'game changer,' thus perceiving high impact on mental health treatments.
Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule with up to 2x the dose showed a fairly large improvement https://t.co/nh4fnmsKqo
⭐ In case you missed it: Generic #ketamine was confirmed to be an effective #antidepressant in people with treatment-resistant #depression. An Australian, @NHMRC-funded, phase 3 trial by @UNSW @georgeinstitute @blackdoginst et al.
Researchers in Australia Demonstrate Efficacy of Ketamine for Treatment-Resistant Depression Over a 4-week Treatment Course "..the proportional increase in remission comparing favourably to that of studies of intranasal esketamine.." https://t.co/Dbeyza12u8
@7NewsMelbourne Why say its linked to mental illness? We are currently using it in trials to treat resistant depression: https://t.co/tK3RsodvPM There are a good number of studies showing that it has positive effects on mental illness. https://t.co/tK3RsodvPM https://t.co/3FA5ANQJO9
#BJPsych Most Downloaded goes to ‘Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial’ by Colleen Loo et al Read the article: https://t.co/sWyOA1HTiI https://t.co/j9uObxmFpv
@Rahmami2585 @MaeWilbon @ChrisTurne83916 @drtessporess @YouTube Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/C4GFbFuzXh via @YouTube
Dr. Tracey Marks discusses ketamine's role in depression treatment, focusing on its mechanism as an NMDA receptor antagonist and neuroplasticity. The video compares FDA-approved Spravato with quetiapine and explores…
Recent research demonstrates the safety and efficacy of a 4-week course of subcutaneous ketamine injections, showing significant remission rates in treatment-resistant depression, with manageable side effects and…
Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/GoBSUkf4i9 via @YouTube
https://t.co/LDK9tkww6g
@MagicMinder @NilsVirago @IsarJesus https://t.co/E1KhzgHvBf
What about these? doi: 10.1192/bjp.2023.79 doi: 10.1176/appi.ajp.2018.18070834 doi: 10.1177/0269881118760660 doi: 10.1192/bjp.2018.196
#BJPsych Most Downloaded goes to ‘Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial’ by Colleen Loo et al Read the article: https://t.co/sWyOA1HTiI https://t.co/j9uObxmFpv
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial | The British Journal of Psychiatry | Cambridge Core https://t.co/pmPHrC2NZV
@francoislegault @JustinTrudeau @POTUS @Eminem Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/gdd1dg4qez via @YouTube Legalise heavy drugs
@Rahmami2585 @MaeWilbon @ChrisTurne83916 @drtessporess @YouTube Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/C4GFbFuzXh via @YouTube
@TatiGrebennique https://t.co/shTXa4aSlA https://t.co/5dAL35LfSB
Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/aqQo6JMNF1
Spravato vs. Seroquel: Ketamine Wins Big in Head-to-Head Depression Battle https://t.co/US6BBnzNIt via @YouTube
https://t.co/iOy98vsBnB
A Phase III trial, found that a 4-week course of subcutaneous ketamine was more effective than midazolam in treating treatment-resistant depression, with a remission rate of 19.6% compared to 2.0% in the flexible-dose cohort. https://t.co/WotnmNkIeX
https://t.co/iOy98vsBnB
RT @MarkHAnderson59: @7NewsMelbourne Why say its linked to mental illness? We are currently using it in trials to treat resistant depress…
@7NewsMelbourne Why say its linked to mental illness? We are currently using it in trials to treat resistant depression: https://t.co/tK3RsodvPM There are a good number of studies showing that it has positive effects on mental illness. https://t.co/tK3RsodvPM https://t.co/3FA5ANQJO9
RCT: Twice-weekly SC racemic ketamine, 0.5–0.9 mg/kg, was more efficacious than midazolam after 4 weeks (remission rate - MADRS OR=12.1; 2.1–69.2), but not different when fixed doses of 0.5 mg(kg were used (1.3; 0.2–8.2). Ketamine was well tolerated https://t.co/BEzchHUsCP https://t.co/pVCoU8RG6s
This trial evaluated the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. https://t.co/ECHYYoiuNJ
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial https://t.co/iuz9nEOzbo
New dog paper! Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial https://t.co/Cgxnz2u7TI
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial https://t.co/XLg0IxUCmT
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial https://t.co/7jgfdMPhMt
@PloederlM @RadoslawStupak Psychologists : psychiatry is dead... Researchers: continue everyday finding better treatments https://t.co/VOSrqFpZlJ
Promising results from @UNSW suggest that ketamine can be used as a new treatment option for severe treatment-resistant depression https://t.co/X1EU2a2shD
RT @DilaraB_PhD: ⭐ In case you missed it: Generic #ketamine was confirmed to be an effective #antidepressant in people with treatment-resis…
⭐ In case you missed it: Generic #ketamine was confirmed to be an effective #antidepressant in people with treatment-resistant #depression. An Australian, @NHMRC-funded, phase 3 trial by @UNSW @georgeinstitute @blackdoginst et al.
RT @GidMK: Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule…
RT @GidMK: Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule…
RT @GidMK: Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule…
RT @GidMK: Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule…
Pretty interesting RCT on ketamine for treatment-resistant depression - no benefit for low doses, but a revised dosing schedule with up to 2x the dose showed a fairly large improvement https://t.co/nh4fnmsKqo
Interesting use for Ketamine, besides Sedation & Anaesthesia. https://t.co/PWq9sIg7ZS https://t.co/cPHHah5F9r
RT @Psyched_Alpha: Researchers in Australia Demonstrate Efficacy of Ketamine for Treatment-Resistant Depression Over a 4-week Treatment Co…
Researchers in Australia Demonstrate Efficacy of Ketamine for Treatment-Resistant Depression Over a 4-week Treatment Course "..the proportional increase in remission comparing favourably to that of studies of intranasal esketamine.." https://t.co/Dbeyza12u8
Study: Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial https://t.co/JAAdpcVibZ https://t.co/NwLbG7BSzN
DOI: 10.1192/bjp.2023.79. 43 Marquina C, Morton J, Brett T, Lloyd M, Radford J, Heal C,. Hespe C, Gill G, Sullivan D, Zomer E, Li I, Pang J, Watts. GF, Ademi Z ...
recruitment while AD preferentially impacts the exteroceptive self with Psychiatry 208, 175–181 https://doi.org/DOI: 10.1192/bjp.bp.114.149971. Fan, Z., Liu ...
... and effectiveness of subcutaneous administration: https://doi.org/10.1192/bjp.2023.79 · DuckWheelz. • 1y ago. I switched to subq six months ...
doi:10.1192/bjp.2023.79. Savage TJ, Kronman MP, Sreedhara SK, Lee SB, Oduol T, Huybrechts KF. Treatment failure and adverse events after ...
doi:10.1192/bjp.2023.79. Savage TJ, Kronman MP, Sreedhara SK, Lee SB, Oduol T, Huybrechts KF. Treatment failure and adverse events after ...
doi: 10.1192/bjp.2023.79. Colleen Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul Fitzgerald et al. 3. BACKGROUND ...
... 10.1192/bjp.2023.79. Conforme a los criterios de Logo Trust Project · ¿Por qué confiar en nosotros? Más información sobre: Salud · Crisis ...
doi:10.1192/bjp.2023.79. 2. University of New South Wales. Ketamine effective for treatment-resistant depression: clinical trial. News ...
The British Journal of Psychiatry, 2023; 1 DOI: 10.1192/bjp.2023.79. Cite This Page: MLA; APA; Chicago. University of New South Wales. "Ketamine ...
... 10.1192/bjp.2023.79. 2. 2 Comments. Please enable JavaScript to view the comments powered by Disqus.
University of Western Australia. Journal. The British Journal of Psychiatry. DOI. 10.1192/bjp.2023.79. Method of Research. Randomized controlled ...
HN
DB
PA
MA
BJ
B
F
GL
P
P
B
SH
D
GP
PM
LN
IL
S
IP
HM
R
G
P
JP